🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🏥Our study on lymph node ratio (LNR) in stage-III colon cancer ➡️LNR: involved nodes/nodes examined ✅adds further prognostication in pN1a-b and N2 TNM stages ❗️Detects patient subgroups in different TNM N sages (pN1a-b and pN2) but with similar prognoses ❗️Adequate and higher

🆕article in press: The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study Elena Rangelova; Thomas Stoop; Tess van Ramshorst; Marc Besselink; Marco Del Chiaro; E-MIPS; CUpancreas; Cancer Center Amsterdam - Amsterdam UMC doi.org/10.1016/j.anno…

🧫Cell-Based Therapies in GI Cancers ASCO ✔️Still long way to go but have a potential 👉doi.org/10.1200/EDBK-2… OncoAlert JCO Precision Oncology #cancer #oncology #MedX

Trastuzumab with or without pertuzumab for peri-op CTx of HER-2+ GC #ASCOGI25 🔎EORTC-1203 GITC INNOVATION 👉mpRR: 23 vs 37 vs 26% 👉3yr OS rate: 75 vs 76 vs 65% 👉High Tox for CTx + T + P 🧐 Negative trial, but high mpRR by adding T to CTx ESMO - Eur. Oncology

That is an excellent point and some food for thought: if pCR is not a good surrogate for survival in GE cancers, what endpoints should we assess, and how should we design future clinical trials?

📘Treatment of dMMR/MSI gastro-oesophageal adenocarcinoma ESMO - Eur. Oncology EORTC ✅Excellent review from biology to management 👉doi.org/10.1016/j.ctrv… Lizzy Smyth Angelica Petrillo OncoAlert #cancer #oncology #MedX

A 33 min overview of GI rad onc! I made this video for an oral boards review course, sharing here. It’s just 5 slides (below) & me talking the whole time, so you can just listen. Hope it’s helpful! Link next post, and short 🧵.

04 de febrero | Día Mundial contra el Cáncer En este Día Mundial contra el Cáncer, unámonos para reescribir el futuro de la atención oncológica, un futuro en el que las necesidades de las personas y las comunidades sean lo primero. #UnidosPorloÚnico

#TumorBoardTuesday 🤔Can Claudin 18.2 be used for Tx💊outside of upper GI Ca❓ 📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd & Katherine Zhou, MD, PhD from Duke University School of Medicine 🗣️Claudin 18.2 as a🎯in #pancreaticcancer RT and bring others into the discussion‼️

Total neoadjuvant treatment, Non-operative management and Radiotherapy-free strategies: New approaches for the management of pMMR/MSS locally advanced rectal cancer. A comprehensive review and evidence-based algorithm ejcancer.com/article/S0959-…

More young adults are getting cancer. Researchers are racing to understand why ti.me/4jZS66T

Hot off the press 🔥 Our views on current management of #advanced #HCC at @myesmo ESMO Gastrointestinal Oncology 📖 📝Summary of current studies 👉Factors for treatment selection Lorenza Rimassa David James Pinato 🇺🇦 Andrea Martirena Fundación Jiménez Díaz Grupo Español de Tratamiento de Tumores Digestivos sciencedirect.com/science/articl…

#mRNAvaccines for #PancreaticCancer (PDAC) PART4 1. Out today in nature nature.com/articles/s4158… 🧵👇🏽 [1/23]

💉Neoadjuvan ChT in colon cancer ASCO ➡️American Cancer Society database ✅OS benefit in T4 tumors ❌But not in T3 👉doi.org/10.1200/OA-24-… OncoAlert #cancer #oncology #MedX

Our latest review on KRAS mutations in early-stage colorectal cancer is out! 🧬 We discuss their prognostic impact, and highlight the importance of routine molecular profiling for better risk stratification and adjuvant therapy decisions. mdpi.com/1648-9144/61/3…

Kidney cancer causes over 150,000 deaths per year worldwide 🌎 Here are a few tips to help prevent it: 1. Don’t smoke 🚭 2. Maintain a healthy weight ⚖️ 3. Control blood pressure 🫀 4. Limit alcohol 🍸 5. Healthy diet 🥬 6. Exercise regularly 🏃🏻‍♀️ 7. Regular health checkups 👩🏻‍⚕️

Early-onset colorectal cancer is expected to become the leading cause of #cancer death in ages 20 to 49 in the U.S. by 2030. Research is urgently needed to better detect and treat patients, argues this #SciencePerspective: scim.ag/4i3RSdS #ColorectalCancerAwarenessMonth

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY- Gastric04 Phase 3 Trial 👉ENHERTU more effective than Pacli/Ram

Expanding the potential of antibody drug conjugates in gastrointestinal malignancies: beyond HER2 targets ESMO Open doi.org/10.1016/j.esmo… 👏Excellent review on ADCs 👉comprehensive review on MOA, resistance mechanism, old & new targets and future directions ESMO - Eur. Oncology

Multidimensional differences in Right vs Left sided Colorectal Ca R & L CRC differ in tumor biology, clinical behavior & response to targeted therapy Shifting from sidedness to molecular classification may better guide treatment decisions OncoAlert rdcu.be/ejgBC